Gilead, Cubist terminate Cidecin deal

The companies mutually terminated their 2001 deal, in which GILD received exclusive European commercialization rights to CBST's Cidecin daptomycin antibacterial injection and an oral formulation of daptomycin. GILD said there is a potential for a more narrow Cidecin label. GILD therefore said it wanted to focus on its internal products, including Viread tenofovir disoproxil for HIV and Hepsera adefovir dipivoxil for hepatitis B virus (HBV) infection. Viread is marketed in the U.S. and Europe, and Hepsera is under review in the U.S. and Europe. ...